Induced Pluripotent Stem Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Derived Cell Type (Hepatocytes, Fibroblasts, Keratinocytes, Neurons, Others), By Application (Drug Development, Regenerative Medicine, Toxicity Testing, Tissue Engineering, Cell Therapy, Disease Modeling), By End user (Research Institutions, Other) By Region & Competition, 2020-2030F

Market Overview

Global Induced Pluripotent Stem Cells Market was valued at USD 1.45 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 9.60% through 2030. The global induced pluripotent stem cells (iPSCs) market has emerged as a dynamic and promising sector within the field of regenerative medicine and cell therapy. iPSCs are specialized cells that can be generated from adult cells and reprogrammed to exhibit pluripotent properties, making them a valuable resource for research and therapeutic applications. One of the primary drivers of the global iPSCs market is the increasing demand for personalized medicine and regenerative therapies. iPSCs offer a unique opportunity to develop patient-specific treatments, reducing the risk of immune rejection and enhancing treatment efficacy. Pharmaceutical companies, academic institutions, and biotechnology firms are investing heavily in iPSC research to develop novel therapies for a wide range of diseases, including cardiovascular disorders, neurodegenerative conditions, and diabetes. Furthermore, the iPSCs market has witnessed substantial growth due to advancements in genome editing technologies such as CRISPR-Cas9, which enable precise manipulation of iPSCs for disease modeling and drug discovery. This has opened new avenues for the development of targeted therapies and the study of genetic disorders. Additionally, the rising prevalence of chronic diseases and an aging population have increased the demand for innovative healthcare solutions, further fueling the iPSCs market's growth. However, challenges such as regulatory hurdles and ethical concerns surrounding iPSC research remain significant roadblocks. Ensuring the safety and ethical use of iPSCs is crucial, and regulatory bodies worldwide are working to establish guidelines and standards for their production and application.

Key Market Drivers

Increasing Prevalence of Chronic Diseases

The growing global burden of chronic diseases including cardiovascular disorders, diabetes, neurodegenerative conditions (such as Alzheimer’s and Parkinson’s), and various forms of cancer is exerting substantial pressure on healthcare systems worldwide. Chronic diseases commonly referred to as non-communicable diseases (NCDs) now account for approximately 75% of global mortality, with cardiovascular disorders, oncology-related conditions, chronic respiratory ailments, and diabetes representing the most significant clinical and economic burdens across both developed and emerging markets. This trend is directly contributing to the accelerated growth of the Induced Pluripotent Stem Cells (iPSCs) market, due to the unique capabilities of iPSCs in disease modeling, drug screening, and regenerative therapy development. Chronic diseases are often progressive, difficult to cure, and require long-term management. Traditional treatment methods frequently fall short in addressing the root causes or achieving lasting results. iPSCs offer a novel therapeutic pathway by enabling the regeneration of diseased or damaged tissue using patient-specific cells. A recent industry survey revealed that 32% of biopharmaceutical executives intend to prioritize high-impact innovations specifically cell and gene therapies leveraging CAR-T and CRISPR technologies over incremental "me-too" drug development. In parallel, 30% of medtech leaders indicated a strategic shift toward investing in novel therapeutic modalities and platform technologies, while 24% are focusing on the advancement of Class III medical devices, favoring complex, high-risk innovations over lower-tier Class II and I solutions. Healthcare providers and biotech companies are actively investing in iPSC-based therapies as a more sustainable and potentially curative alternative to conventional treatment protocols.

iPSCs can be reprogrammed from a patient’s somatic cells and differentiated into disease-relevant cell types, allowing researchers to develop accurate in vitro models of complex chronic conditions. These models are essential for understanding disease mechanisms, testing new drug compounds, and identifying potential therapeutic targets. Pharmaceutical and biotech companies leverage these models to reduce R&D risk, shorten development timelines, and increase the success rate of clinical trials, especially in areas like oncology and neurological diseases. According to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 globally are currently living with diabetes nearly half of whom remain undiagnosed, underscoring a critical gap in disease awareness and early intervention. Looking ahead, projections indicate a sharp escalation, with diabetes expected to affect 1 in 8 adults approximately 783 million people by 2045, representing a 46% increase and signaling a growing healthcare and economic burden across global markets. As the prevalence of diseases such as Type 1 diabetes, Parkinson’s disease, or heart failure increases, iPSCs can be used to generate functional cells or tissues for transplantation, effectively replacing cells that have been lost or damaged over time. The regenerative capabilities of iPSCs are opening new revenue streams for cell therapy developers, while also attracting significant interest from healthcare investors and institutional funding agencies. For patients suffering from chronic conditions, particularly those with rare or complex disease subtypes, iPSCs can be used to test the efficacy and safety of drugs on a personalized cellular platform, helping tailor treatments to individual patient responses. This personalized approach aligns with precision medicine initiatives and increases the commercial appeal of iPSC technologies to pharmaceutical companies aiming to differentiate their drug development pipelines.

Rising Geriatric Population

The steady increase in the global aging population is a major factor propelling the demand for innovative healthcare solutions, including advanced cell-based therapies. The global population aged 60 and above is projected to rise from 1 billion in 2020 to 1.4 billion in the near term. By 2050, this demographic will double, reaching approximately 2.1 billion. Notably, the segment aged 80 and older is expected to experience the most significant growth tripling over the same period to 426 million signaling a substantial shift in healthcare demand, long-term care infrastructure, and age-focused innovation across global markets. The unique capabilities of induced pluripotent stem cells (iPSCs)—particularly in regenerative medicine, disease modeling, and drug development position them as a highly promising solution to meet the healthcare needs of elderly populations. As a result, the rise in the geriatric demographic is contributing significantly to the expansion of the global iPSCs market. Age-associated diseases such as atherosclerosis, cardiovascular conditions, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes, hypertension, and Alzheimer’s show a sharply exponential increase in incidence with advancing age. Of the approximately 150,000 global deaths occurring daily, two-thirds (around 100,000) are attributed to age-related conditions. In industrialized economies, this figure rises to nearly 90%, underscoring the urgent need for age-targeted healthcare solutions, therapeutic innovation, and preventive strategies tailored to aging populations. iPSCs offer the ability to generate patient-specific cells that can be used to better understand these diseases, develop targeted drugs, or even regenerate damaged tissues. The growing demand for effective treatments of age-related diseases is driving significant investment in iPSC-based research and therapeutic development, creating robust commercial opportunities for biotech and pharmaceutical companies.

As the body ages, the natural ability to regenerate tissues declines. This creates an unmet need for regenerative medicine, where iPSCs are increasingly being used to develop therapies aimed at repairing or replacing aged or damaged tissues and organs. Companies that offer iPSC-based regenerative therapies stand to benefit from a rapidly expanding market segment focused on elderly patients, particularly in orthopedics, cardiology, neurology, and ophthalmology. Older adults often experience multiple chronic conditions, requiring a personalized approach to therapy to avoid drug interactions and optimize treatment outcomes. iPSCs enable the creation of individualized cellular models, facilitating the development of safer and more effective therapies tailored to elderly patients. Personalized treatment solutions using iPSC technology appeal to healthcare providers and insurers seeking to improve quality of care while managing costs in aging populations. There is a growing focus on geriatric-specific clinical research, which seeks to understand how aging impacts the efficacy and safety of treatments. iPSC-derived cell lines from elderly individuals are now being used to model aging-related diseases and test pharmacological compounds in age-relevant cellular environments. This trend is fueling demand for iPSC services in research and development settings, creating new business models for CROs, academic labs, and biotech firms.

Expanding Research Infrastructure

The expansion of research infrastructure is a critical driver behind the growth of the global induced pluripotent stem cells (iPSCs) market. iPSCs hold immense promise for regenerative medicine, disease modeling, and drug discovery, but their realization requires advanced research facilities, equipment, and expertise. As the iPSCs field continues to evolve, research institutions, academic centers, and biotechnology companies are actively investing in building and enhancing research infrastructure to unlock the full potential of iPSCs. Advanced research infrastructure encompasses cutting-edge laboratories equipped with state-of-the-art instruments for cellular reprogramming, differentiation, and genetic editing. These facilities are essential for the generation and manipulation of iPSCs, as well as for conducting experiments related to their applications. As research institutions upgrade their facilities, it becomes easier for scientists to work with iPSCs, accelerating the pace of discoveries and developments.

In addition to laboratory infrastructure, the iPSCs market benefits from the expansion of collaborative networks and research consortia. Many research institutions collaborate across borders, sharing knowledge and resources to advance iPSC research collectively. These collaborations foster interdisciplinary approaches, enabling researchers to address complex challenges more effectively and explore a broader range of applications, from regenerative therapies to disease modeling and drug screening. Furthermore, the growth of research infrastructure has led to the establishment of dedicated iPSC research centers and institutes. These specialized facilities serve as hubs for iPSC-related research, offering specialized training programs and fostering a collaborative environment. They attract top talent in the field and provide critical support for innovation and development in iPSC-based therapies and technologies. The impact of expanding research infrastructure extends beyond academia, influencing the biopharmaceutical industry as well. Pharmaceutical and biotechnology companies are increasingly partnering with research institutions and investing in their own iPSC research centers. This industry-academia collaboration is pivotal for translating iPSC discoveries into clinical applications, ultimately benefiting patients through the development of cutting-edge therapies. 

Download Free Sample Report

Key Market Challenges

Safety and Efficacy Concerns

Safety and efficacy concerns stand out as a significant hindrance to the growth of the global induced pluripotent stem cells (iPSCs) market. While iPSCs hold immense promise in regenerative medicine and personalized therapies, there are several critical challenges that must be addressed to ensure their clinical application. One of the foremost concerns is the safety of iPSC-based therapies. When iPSCs are used to generate differentiated cell types for transplantation or disease modeling, there is a risk of tumorigenesis. iPSCs can potentially form teratomas, tumors composed of various cell types, when transplanted into patients. These tumorigenic risks pose a substantial obstacle to the clinical translation of iPSC-based treatments, as patient safety must always be paramount. Moreover, immune rejection is another safety concern. Despite being generated from a patient's own cells, iPSC-derived cells may not always be perfectly matched to the patient's immune system. Ensuring compatibility and preventing immune responses is a critical challenge, particularly in allogeneic iPSC-based therapies where cells are derived from donors other than the patient.

In addition to safety concerns, there are efficacy challenges to address. Demonstrating the efficacy of iPSC-based therapies through rigorous preclinical and clinical trials is essential. These therapies must not only be safe but also provide meaningful therapeutic benefits. The complexities of evaluating their long-term efficacy, especially in chronic and degenerative diseases, add to the challenge. Furthermore, standardization of iPSC production and differentiation protocols is essential to ensure consistent and reliable outcomes. Variability in iPSC quality, differentiation efficiency, and the functional characteristics of iPSC-derived cells can hinder the reproducibility of results and the reliability of iPSC-based treatments.

Regulatory Hurdles

Regulatory hurdles represent a significant impediment to the growth of the global induced pluripotent stem cells (iPSCs) market. iPSCs hold immense potential for regenerative medicine and therapeutic applications, but navigating the complex and evolving regulatory landscape poses substantial challenges. One of the primary issues stems from the need to establish comprehensive and consistent regulatory guidelines for iPSCs. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are tasked with ensuring the safety and efficacy of new therapies. However, iPSCs' unique characteristics, including their potential to differentiate into various cell types and the personalized nature of their applications, require tailored regulatory frameworks. The lack of clear and harmonized regulations can create ambiguity and hinder research, development, and clinical translation.

Additionally, iPSC-based therapies often involve genetic modifications, introducing another layer of regulatory complexity. Editing the genetic material of iPSCs raises concerns about safety, off-target effects, and ethical considerations. Regulatory agencies are challenged with developing guidelines that strike a balance between promoting innovation and ensuring patient safety. Furthermore, the time and resources required to navigate the regulatory approval process can be daunting for researchers and companies in the iPSCs market. Clinical trials for iPSC-based therapies often demand extensive data collection, long-term follow-up, and robust safety assessments.

Key Market Trends

Personalized Medicine and Patient-Specific Therapies

One of the most significant trends driving the iPSCs market is the increasing emphasis on personalized medicine. Healthcare providers and researchers are recognizing that one-size-fits-all treatments may not be the most effective approach for many diseases. iPSCs allow for the creation of patient-specific therapies by reprogramming a patient's own cells, reducing the risk of immune rejection and increasing treatment efficacy. This trend aligns with the growing demand for tailored healthcare solutions, particularly in the treatment of chronic and complex diseases. iPSCs provide a powerful tool for developing patient-specific therapies. By reprogramming a patient's own cells into iPSCs, researchers can generate a source of cells that closely match the patient's genetic profile. This personalized approach reduces the risk of immune rejection, enhances treatment efficacy, and minimizes adverse reactions. For patients with genetic disorders, iPSCs offer a beacon of hope. Researchers can correct disease-causing mutations in iPSCs, effectively "fixing" the genetic basis of the disorder. These corrected iPSCs can then be differentiated into the required cell types, providing a potential cure for conditions that were previously considered untreatable. iPSCs allow for the creation of disease models that replicate the unique characteristics of a patient's ailment. These models enable researchers to study disease mechanisms, test potential therapies, and develop personalized treatment strategies. iPSC-derived disease models enhance our understanding of complex diseases, driving innovation in treatment approaches. Patient-specific iPSC-based therapies hold the promise of reducing adverse effects commonly associated with traditional treatments. By closely matching the patient's genetic and immunological profile, iPSC-derived cells are more likely to be tolerated by the body, minimizing side effects and improving overall treatment outcomes.

Advancements in Genome Editing Technologies

Advancements in genome editing technologies, notably CRISPR-Cas9, have revolutionized iPSC research. These tools enable precise genetic modifications in iPSCs, making it possible to correct disease-causing mutations and develop more accurate disease models. Researchers can now study the genetic basis of various conditions and develop targeted therapies with greater efficiency. This trend has accelerated drug discovery efforts and has further increased the appeal of iPSCs in the biopharmaceutical industry. CRISPR-Cas9 allows scientists to make precise modifications to the genetic material of iPSCs. This capability is invaluable for creating disease models and developing potential cures. Researchers can correct genetic mutations associated with various diseases, providing a deeper understanding of their underlying mechanisms and accelerating the discovery of novel therapies. iPSCs, when combined with genome editing, enable the development of sophisticated disease models. Researchers can introduce disease-specific mutations or correct faulty genes to mimic specific diseases in a laboratory setting. These models provide a realistic platform for studying disease progression, testing potential treatments, and gaining insights into disease mechanisms. Genome editing allows for the creation of iPSCs that are custom-tailored to an individual patient's genetic profile. This is a significant step toward personalized medicine. By reprogramming a patient's own cells and precisely modifying them as needed, researchers can generate iPSC-derived cells for transplantation or disease modeling that are inherently compatible with the patient's immune system. The combination of iPSCs and genome editing has revolutionized drug discovery efforts. iPSC-derived cells carrying disease-specific mutations provide a more physiologically relevant platform for evaluating the safety and efficacy of new drug candidates. This reduces the risk of drug failures in later stages of development, saving time and resources for pharmaceutical companies.

Segmental Insights

Application Insights

Based on the application, the drug development segment emerged as the fastest growing segment in the global market for Global Induced Pluripotent Stem Cells in 2024. Traditional preclinical models, particularly those relying on animal testing, often fail to accurately replicate human biological responses. iPSCs, by contrast, allow researchers to derive disease-relevant human cell types from genetically diverse populations, enabling the development of high-fidelity in vitro models for drug screening and toxicology. Pharma companies are increasingly integrating iPSC-derived cells into early-stage research to reduce attrition rates, improve translational success, and shorten the time-to-market for new drug candidates. The rise of precision medicine is fundamentally changing how therapies are developed and tested. iPSCs can be derived from individuals with specific genetic backgrounds, making them ideal for patient-specific drug screening, especially for rare and genetically complex diseases. This capability enables pharmaceutical firms to stratify patient populations more effectively, optimize clinical trial design, and pursue niche indications with higher therapeutic precision and commercial viability.

Derived Cell Type Insights

Based on the Derived Cell Type, the hepatocytes segment emerged as the dominant player in the global market for Global Induced Pluripotent Stem Cells in 2022. This is on account of Hepatocytes being a critical cell type in the iPSCs market, primarily due to their significant role in liver disease modeling, drug metabolism studies, and drug toxicity testing. They are essential for understanding how drugs are processed in the liver and for identifying potential liver-related side effects of pharmaceutical compounds. Hepatocytes are also used to study liver diseases such as hepatitis and cirrhosis, making them a valuable asset in drug development and disease research.

Download Free Sample Report

Regional Insights

North America emerged as the largest market in the global Induced Pluripotent Stem Cells market in 2024, holding the largest market share. North America particularly the United States is home to a significant concentration of global pharmaceutical giants, biotech innovators, and contract research organizations (CROs) that are actively investing in iPSC-based research and development. These organizations are leveraging iPSCs across a wide range of applications, from disease modeling and drug discovery to personalized therapies and regenerative medicine. This concentration of industry leaders ensures a high level of ongoing investment, collaboration, and commercialization activity, strengthening the region’s dominance in the iPSCs market.

Top-tier academic institutions, such as Harvard, Stanford, and the University of California system, are global pioneers in stem cell research, including iPSC innovations. These institutions often collaborate with industry players to accelerate translational research and develop cutting-edge iPSC platforms. Academic-industry partnerships foster faster technology transfer, clinical validation, and commercialization of iPSC-based solutions. The U.S. government, through agencies such as the National Institutes of Health (NIH), allocates substantial funding for regenerative medicine and cell-based research, with a growing focus on iPSCs. In addition, private venture capital and institutional investors are heavily backing iPSC-focused startups and spin-offs. Reliable access to both public and private capital fuels innovation and scales the development of commercially viable iPSC-based products and services.

Recent Developments

• In August 2024, Shinobi Therapeutics, a biotechnology firm focused on developing a next-generation class of immune-evasive iPSC-based cell therapies, has announced a strategic partnership with Panasonic Holdings Corporation and Kyoto University’s Center for iPS Cell Research and Application (CiRA). The collaboration is aimed at co-developing an advanced manufacturing platform designed to enable more scalable, cost-effective production of iPSC-derived T cell therapies significantly improving upon the limitations of current manufacturing technologies.
• In August 2024, Researchers at Brigham and Women’s Hospital, supported by the American Parkinson Disease Association (APDA), have developed a novel technology that significantly accelerates the differentiation of adult-derived induced pluripotent stem cells (iPSCs) into brain cells. These cells successfully replicate key pathological features, including the accumulation of alpha-synuclein a hallmark protein linked to neurodegenerative disorders such as Parkinson’s disease offering a more efficient and disease-relevant model for therapeutic research and drug screening.
• In October 2023, STEMCELL Technologies, Canada’s leading biotechnology company, has officially expanded its national footprint with the launch of a new sales office located at the MaRS Centre in downtown Toronto, Ontario. This strategic move enhances the company’s presence in one of the country’s most prominent innovation hubs, supporting closer engagement with Ontario’s thriving life sciences and research communities.
• In October 2023, The integration of ASC’s advanced technological capabilities with QHP’s strategic network and deep industry expertise will accelerate our mission to shape the future of the cell and gene therapy market. Together, we aim to develop iPSC-derived cell products that deliver superior efficacy, uncompromising safety, and highly scalable, accelerated manufacturing solutions.

Key Market Players

• Axol Bioscience Ltd.
• Cynata Therapeutics Limited
• Evotec SE
• Fate Therapeutics, Inc.
• FUJIFILM Cellular Dynamics, Inc.
• Ncardia
• LizarBio Therapeutics (Pluricell Biotech)
• Reprocell USA, Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Takara Bio, Inc.

Report Scope:

In this report, the Global Induced Pluripotent Stem Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Induced Pluripotent Stem Cells Market, By Derived Cell Type:

o   Hepatocytes

o   Fibroblasts

o   Keratinocytes

o   Neurons

o   Others

• Induced Pluripotent Stem Cells Market, By Application:

o   Drug Development

o   Regenerative Medicine

o   Toxicity Testing

o   Tissue Engineering

o   Cell Therapy

o   Disease Modeling

• Induced Pluripotent Stem Cells Market, By End User:

o   Research Institutions

o   Other

• Induced Pluripotent Stem Cells Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Market.

Available Customizations:

Global Induced Pluripotent Stem Cells market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Induced Pluripotent Stem Cells Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com